Multi-Omics and NGS Technologies Propel Gynecological Cancer Diagnostics Toward Double-Digit Growth

According to the latest market research study published by P&S Intelligence, the global next-generation gynecological cancer diagnostics market is undergoing a transformative shift, with its size projected to surge from USD 2.98 billion in 2024 to USD 6.09 billion by 2032, growing at a CAGR of 9.5%. This rapid expansion is fueled by the rising prevalence of gynecological malignancies, advancements in precision diagnostics, and increasing investment in women’s healthcare.

Download free Report Sample Now

Market Drivers: A Convergence of Healthcare Needs and Innovation

• Rising cancer incidence: Uterine, ovarian, and cervical cancers remain the most common gynecological malignancies worldwide, intensifying the demand for early and accurate diagnostics.
• Lifestyle-related factors: Obesity, diabetes, menopause-related health issues, and hormonal imbalances linked to diet are contributing to higher cancer risks among women.
• Government and regulatory support: Favorable policies, global awareness campaigns, and healthcare investments are accelerating access to advanced screening technologies.
• Technological innovation: Next-generation sequencing (NGS), DNA microarrays, and AI-powered multi-omics approaches are revolutionizing early cancer detection and enabling personalized treatment strategies.

Emerging Trends: Multi-Omics and AI Integration

One of the most significant trends shaping this market is the adoption of multi-omics approaches. These advanced methods identify unique molecular signatures of gynecological cancers, allowing earlier and more accurate diagnosis.

• In India, the Indian Cancer Genome Atlas is pioneering national-level cancer multi-omics mapping, strengthening research and precision medicine capabilities.
• Companies like Owkin are integrating AI and spatial omics to accelerate biomarker discovery and improve clinical trial outcomes, exemplified by the MOSAIC project.
• Regulatory frameworks such as GDPR, OECD guidelines, and ICH standards are ensuring data privacy, ethical practices, and global compliance in multi-omics adoption.

Market Segmentation Highlights

• Technology: NGS leads with a 65% market share in 2024, while DNA microarrays are projected to grow at the fastest rate.
• Cancer Type: Uterine cancer dominates with 60% share; however, cervical cancer diagnostics is expected to grow at the highest CAGR due to rising prevalence.
• End User: Hospitals and ambulatory centers hold the largest share (75%), while academic and research institutes will see the fastest growth.

Regional Growth Dynamics

• North America remains the largest market (40% share), driven by strong healthcare infrastructure, insurance coverage, and early adoption of advanced diagnostics.
• Europe is set to grow at the fastest CAGR, led by Germany, the U.K., and France, supported by government programs and rapid technology adoption.
• Asia-Pacific is emerging as a high-growth region, particularly in China and India, where government-backed genomic projects and healthcare infrastructure expansion are fueling demand.

Competitive Landscape

The market is consolidated, with key players including Roche, Thermo Fisher Scientific, Illumina, Myriad Genetics, Hologic, and Agilent Technologies, holding significant global presence through R&D investments and strategic partnerships.

Recent Developments:

• June 2024: Thermo Fisher Scientific signed an MoU with National University Hospital (NUH) and Mirxes to advance NGS genomic testing tailored for Southeast Asian populations.
• March 2025: Agilent Technologies partnered with Hamamatsu, PathAI, Proscia, and Visiopharm to launch an AI-powered end-to-end diagnostic workflow for tissue analysis.

Looking Ahead

With continued innovation, rising global cancer incidence, and growing demand for personalized treatment strategies, the Next-Generation Gynecological Cancer Diagnostics Market is set to play a transformative role in women’s healthcare worldwide.

Read More

APAC and Emerging Economies Poised to Drive Rapid Growth in Patient Handling Equipment Sector

According to the latest market research study published by P&S Intelligence, the global patient handling equipment market is on a remarkable growth trajectory, with its market size projected to expand from USD 14.5 billion in 2024 to USD 20.4 billion by 2032, reflecting a steady CAGR of 4.5%. This growth is primarily driven by the rising prevalence of disabilities, increasing road accidents, enhanced post-treatment care, and significant improvements in healthcare infrastructure worldwide.

Download free Report Sample Now

Key industry developments, including stringent government regulations aimed at ensuring the safety of healthcare workers during manual lifting processes, are further propelling market expansion. Regulatory bodies such as CDC, EU-OSHA, WSHC, and the National Institute of Occupational Safety & Health (NIOSH) have established guidelines like the Recommended Weight Limit (RWL) to ensure safer patient management, reducing injury risks for caregivers.

The increasing global incidence of musculoskeletal disorders, which affect over 1.5 billion people, is driving demand for patient handling equipment that supports effective rehabilitation and mobility. Additionally, emerging economies are presenting untapped opportunities for growth due to rising patient admissions and expanding healthcare infrastructure.

Regional Growth Highlights:

• Europe leads the market with a 30% share, fueled by strong government initiatives, supportive regulations, and the presence of major market players.
• The APAC region is set to be the fastest-growing market at a CAGR of 6.2%, driven by rapid medical industry expansion, government support, and rising lifestyle-related disorders. Countries like China and India show enormous potential, with large populations, improving healthcare facilities, and cost-effective manufacturing attracting key medical device players.

Market Segmentation Insights:

• By Type: Medical beds accounted for the largest share (35%) in 2024, thanks to technological innovations in ICU and electric beds. Mobility devices, including wheelchairs and ambulatory aids, represent the fastest-growing segment due to increasing home healthcare demands.
• By Care Type: Acute care held the largest share (40%), while long-term care is anticipated to grow at the highest CAGR of 4.8%, reflecting the trend toward home-based and personalized care for elderly patients.
• By End User: Hospitals dominate the market with a 40% share, whereas home healthcare is the fastest-growing category, propelled by government reimbursement programs and rising patient preference for at-home care.

Market Drivers:

• Growing geriatric population and rising chronic diseases are increasing demand for patient handling equipment. WHO projects that by 2030, one in six people will be over 60, emphasizing the need for specialized medical devices.
• Expanding home healthcare services supported by initiatives such as the US Centers for Medicare & Medicaid Services (CMS) and India’s National Programme for Health Care of the Elderly (NPHCE) are significantly boosting market growth.

Competitive Landscape:

The market is highly fragmented with leading players including Arjo, Stryker Corporation, Baxter International, Savaria Corporation, Joerns Healthcare, Invacare, Sunrise Medical, Permobil AB, and others. These companies are innovating with smart, automated, and ergonomic solutions to improve patient safety, comfort, and operational efficiency. Recent product launches, such as Etac AB’s R82 Chilla pediatric buggy and Gf Health Products’ Hausted 5B800ST stretcher, highlight the ongoing innovation in this sector.

With continuous advancements in healthcare technology, supportive regulatory frameworks, and rising demand for patient-centered care, the Patient Handling Equipment Market is poised for sustained growth, offering promising opportunities for industry stakeholders, investors, and healthcare providers globally.

Read More

North America is Dominating Next-Generation Gynecological Cancer Diagnostics Industry

In 2022, the global next-generation gynecological cancer diagnostics market had a total size of USD 2,396 million, and it is projected to hit USD 5,135 million by 2030, progressing at a rate of 10% from 2022 to 2030, according to a research report by a market research company P&S Intelligence. 

To learn more about this report: https://bit.ly/3VWcg6c

This growth can be credited to the growing occurrence of gynecological malignancies, variations in lifestyle and overweightness in women, growing cases of menopause issues, and the increasing occurrence of diabetes. Moreover, a bad diet and extreme consumption of soy products, flaxseeds, and Vitamin D are accountable for high estrogen levels in the body that sources cancer.

Cervicovaginal human papillomavirus is one of the most generally affected sexually communicated illnesses in both women and men, which primarily causes cervical and other solid tumors (vaginal, vulvar). Around 200 genetic kinds have been discovered, and they are segmented into the high-risk genotype and low-risk genotype, on the basis of their carcinogenic nature.

In 2022, the uterine cancer category held the largest next-generation gynecological cancer diagnostics market share, of above 30%, and the category is projected to be dominant throughout the forecast period.

This can be credited to the growing cases of uterine cancer worldwide, because of the rising aging women populace, rising menopause problems after the age of 55, the growing occurrence of high blood sugar levels and blood pressure, and growing situations of obesity and high estrogen levels.

In 2022, North America dominated the industry with the largest market share, of above 40%, and the continent is projected to be dominant throughout the forecast period. This is mainly because of the growing cases of cervical and gynecological malignancies in the continent. These are very stressful situations and aid in the acceptance of diagnosis methods.

Hence, the growing occurrence of gynecological malignancies, variations in lifestyle and overweightness in women, growing cases of menopause issues, and the increasing occurrence of diabetes are the major factors propelling the market.

Read More